The connected home platform for seniors and caregivers. Quil Assure is here to relieve the stresses of caregivers and care receivers. The all-in-one platform helps manage care – filling in gaps, sending alerts and keeping track of vital patterns and routines, all while maintaining the privacy seniors desire. Simply put, Quil Assure works to relieve burdens by restoring the independence of seniors and taking weight off of the shoulders of caregivers.

nQ Medical is a digital therapeutics company addressing neurocognitive and neuromotor disorder via 24/7, passive data collection via personal devices. It is a frictionless, non-invasive, early detection, remote disease progression monitoring, and therapeutic measurement modality. nQ uses an artificial intelligence company to develop computational biomarkers that have been proven in five years of clinical trials to substantially change the way disease is managed for a wide range of neuromotor and neurocognitive disorders (Alzhemer's, Parkinson's, Multiple Sclerosis, ALS, concussion, et al. The platfomr focuses on analysis of user interaction with common electronic devices to capture functional decline related to neurodegenerative disorders. The fine control of typing and touch screen kinematics together with the frequent use of electronic devices allows for precise monitoring of small changes in neurodegeneration that frequently go unnoticed by clinicians. nQ allows for early detection of disease, 24/7, passive, at home, remote monitoring of disease progression and the measurement of impact of therapy at a fraction of the cost of current gold standards. There is no required task. Just use your device as your would normally use it. Of note, as one of the company's medical advisors, Zoltan Mari, MD, of the Cleveland Clinic, so aptly quoted: "As important as it is to fund novel compounds for treating diseases, it is also important to set the stage for maximum impact when those compounds are discovered and approved for use. It is impossible to find a cure without early detection. That's why drug candidates fail. When the FDA puts its stamp on the first disease modifying drugs, such early detection technologies will be instantly necessary." He goes on to state further: "We also need a disease progression marker. Nothing so far has managed to do very well (while being profoundly expensive). Much of our research and clinical interest is turning toward disease progression. All efforts should focus on readying and perfecting early detection tools and building effective, reliable, inexpensive ways of tracking disease and the impact of therapy over time.” nQ is that early detection, disease progression computational biomarker.